Ensidipine usage and dosage?

Ensidipine (enasidenib) is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor developed by Celgene Corporation under an exclusive worldwide license from Agios Pharmaceuticals. In the United States, ensidipine is approved for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) and IDH2 mutations detected by an FDA-approved test.

The recommended dose of ensidipine is 100 mg orally once daily with or without food until disease progression or unacceptable toxicity occurs. For patients without disease progression or unacceptable toxicity, treat for at least 6 months to allow time for clinical response. Do not split or crushensidipinetablets. Take ensidipinetablets by mouth at about the same time each day. If a dose of ensidipine is vomited, missed, or not taken at the usual time, take the dose as soon as possible that day and resume the normal time the next day.

Before initiatingensidipine, assess blood counts and blood chemistries for leukocytosis and tumor lysis syndrome and monitor at least every 2 weeks for at least the first 3months of treatment and manage any abnormalities promptly. Ensidipine is available in two specifications, 50mg tablets:Light yellow to yellow oval film-coated tablets, with "ENA" debossed on one side and "50" debossed on the other side. 100mg tablets:Light yellow to yellow capsule-shaped film-coated tablets, with "ENA" debossed on one side and "100" debossed on the other side. The retail price of pharmaceutical factories in Bangladesh is about 4,000 to 5,000 per box, and the retail price of pharmaceutical factories in Laos is about 2 thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.